Anlotinib Combined with S‐1 in Third‐ or Later‐Line Stage IV Non‐Small Cell Lung Cancer Treatment: A Phase II Clinical Trial

LESSONS LEARNED: The combination of anlotinib and S‐1 exhibited good antitumor activity in third‐ or later‐line treatment for stage IV non‐small cell lung cancer (NSCLC). Combination therapy of anlotinib with S‐1 has manageable toxicities in patients with NSCLC. BACKGROUND: This study aimed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Miao, Yang, Xiyue, Ren, Surong, Du, Huan, Geng, Lidan, Yuan, Li, Wen, Yixue, Lin, Binwei, Li, Jie, Zhang, Yu, Feng, Gang, Du, Xiaobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649049/
https://www.ncbi.nlm.nih.gov/pubmed/34423518
http://dx.doi.org/10.1002/onco.13950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649049/
https://www.ncbi.nlm.nih.gov/pubmed/34423518
http://dx.doi.org/10.1002/onco.13950

Ejemplares similares